Benzinga | Feb 19, 2021 08:06AM EST

Chardan Capital Downgrades Emergent BioSolutions to Neutral, Announces $112 Price Target

Chardan Capital analyst Keay Nakae downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Neutral and announces $112 price target.